Basic Study
Copyright ©The Author(s) 2018.
World J Clin Cases. Aug 16, 2018; 6(8): 183-191
Published online Aug 16, 2018. doi: 10.12998/wjcc.v6.i8.183
Table 1 Serum hepatitis B surface antigen levels in transgenic mice (n = 7, mean ± SD)
GroupsBefore treatmentAfter treatment
Day 1Day 3Day 5Day 7
Blank2.34 ± 0.222.33 ± 0.232.32 ± 0.312.37 ± 0.302.35 ± 0.21
USQ2.35 ± 0.362.34 ± 0.252.37 ± 0.312.31 ± 0.452.36 ± 0.38
LAM2.33 ± 0.282.31 ± 0.382.27 ± 0.242.21 ± 0.232.15 ± 0.19
Anti-S-LNA2.31 ± 0.272.03 ± 0.281.61 ± 0.111.55 ± 0.161.33 ± 0.26
Anti-G-LNA2.35 ± 0.331.92 ± 0.401.59 ± 0.32 ab1.27 ± 0.29ab0.96 ± 0.18abc
Table 2 Effects of anti-gene-locked nucleic acid on hepatitis B virus deoxyribonucleic acid replication and expression in transgenic mice (n = 7, mean ± SD; × 103 IU/mL)
GroupsBefore treatmentAfter treatment
Day 1Day 3Day 5Day 7
Blank10.81 ± 1.1510.80 ± 0.7810.86 ± 1.8510.80 ± 1.1910.77 ± 1.25
USQ11.12 ± 0.8711.25 ± 0.9411.16 ± 0.9611.06 ± 0.8511.08 ± 0.89
LAM10.96 ± 1.0810.93 ± 1.1210.62 ± 0.8910.07 ± 1.379.73 ± 1.17
Anti-S-LNA10.92 ± 1.098.94 ± 0.896.91 ± 1.265.48 ± 0.975.79 ± 0.92
Anti-G-LNA11.05 ± 1.259.12 ± 0.966.79 ± 1.16ab5.42 ± 1.12ab4.17 ± 1.29abc